(Total Views: 605)
Posted On: 02/17/2021 11:18:52 PM
Post# of 72444
Eff the crooks! Woo hoo!
Protocol IPI-BRIc-201
Protocol name
Phase II Double-Blind Placebo-Controlled Randomized Multicenter Study to Evaluate the Effectiveness and Safety of Brilacidine in Patients Hospitalized with COVID-19
Therapeutic area
Anaesthesiology and Resuscitation, Infectious Diseases, Oncology, Therapy (General), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
17.12.2020 - 31.03.2021
Number and date of RKI
No. 705 of 17.12.2020
Organization conducting CI
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Name of PL
Brilacidine
Medicinal form and dosage
intravenous solution, 50 mg/ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Country of developer
США
Organization engaged by the PL developer
iPharma LLC, 143026, Moscow. Moscow, territory of the Skolkovo Innovation Center, ul. 7 Nobel St., Russia
CI phase
II
View of CI
MMKI
Purpose of CI
assessment of the effectiveness and safety of Brilacidine in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Protocol IPI-BRIc-201
Protocol name
Phase II Double-Blind Placebo-Controlled Randomized Multicenter Study to Evaluate the Effectiveness and Safety of Brilacidine in Patients Hospitalized with COVID-19
Therapeutic area
Anaesthesiology and Resuscitation, Infectious Diseases, Oncology, Therapy (General), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
17.12.2020 - 31.03.2021
Number and date of RKI
No. 705 of 17.12.2020
Organization conducting CI
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Name of PL
Brilacidine
Medicinal form and dosage
intravenous solution, 50 mg/ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Country of developer
США
Organization engaged by the PL developer
iPharma LLC, 143026, Moscow. Moscow, territory of the Skolkovo Innovation Center, ul. 7 Nobel St., Russia
CI phase
II
View of CI
MMKI
Purpose of CI
assessment of the effectiveness and safety of Brilacidine in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
(16)
(0)
***On 02/26/2016 at 8:33 am Scottsmith admited to posting under 5 aliases but his post was subsequently deleted. I have a screen shot and will email it to anyone interested.
Scroll down for more posts ▼
